Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin☆
References (66)
- et al.
Fetal survival after prednisone suppression of maternal lupus-anticoagulant
Lancet
(1983) - et al.
Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody
Am J Obstet Gynecol
(1989) - et al.
Recurrent adverse pregnancy outcome and antiphospholipid antibodies
Am J Obstet Gynecol
(1990) - et al.
Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization
Am J Obstet Gynecol
(1988) - et al.
Successful removal of anti-phospholipid antibody during pregnancy using plasma exchange and lowdose prednisolone [letter]
Lancet
(1987) - et al.
Plasma exchange and the anticardiolipin syndrome in pregnancy [letter]
Lancet
(1989) - et al.
A standard of fetal growth for the United States of America
Am J Obstet Gynecol
(1976) - et al.
Cytotoxic antibody against trophoblast and lymphocytes present in pregnancy with intrauterine fetal growth retardation and its relation to anti-phospholipid antibody
J Reprod Immunol
(1990) - et al.
Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial
Lancet
(1991) - et al.
Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus
Am J Med
(1985)
Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss
Am J Obstet Gynecol
Anticardiolipin antibodies in polymyalgia rheumatica-giant cell arteritis: association with severe vascular complications
Am J Med
Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant
Am J Obstet Gynecol
Arterial thrombosis, intrauterine death and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation
Lancet
Pathophysiology of antiphospholipid antibodies: absence of prostaglandin-mediated effects on cultured endothelium
Am J Obstet Gynecol
Lupus anticoagulant inhibition of in vitro prostacyclin release is associated with a thrombosis-prone subset of patients
Am J Med
Preeclampsia: an imbalance in placental prostacyclin and thromboxane production
Am J Obstet Gynecol
Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole
Am J Obstet Gynecol
Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man
Prostaglandins
Low-dose aspirin in pregnancy [letter]
Lancet
Antiphospholipid antibodies—autoantibodies with a difference
Annu Rev Med
The anticardiolipin syndrome [editorial]
J Rheumatol
A reassessment of the antiphospholipid syndrome [editorial]
J Rheumatol
Obstetric complications associated with the lupus anticoagulant
N Engl J Med
Fetal loss treatment in patients with antiphospholipid antibodies
Ann Rheum Dis
Anticardiolipin antibodies (ACA) and pregnancy [abstract]
Am J Obstet Gynecol
Management of recurrent fetal loss in patients with antiphospholipid antibody and/or lupus anticoagulant—a survey of Kingston anti-phospholipid antibody study group certified centers [abstract]
Clin Res
Outcome of treatment in healthy women with positive anticardiolipin antibody (ACA) and a history of habitual abortions [abstract]
Arthritis Rheum
Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies
Obstet Gynecol
Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus
N Engl J Med
Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986
Clin Exp Immunol
Preterm and postterm pregnancy and inappropriate fetal growth
The newborn infant
Cited by (97)
Effects of low-dose aspirin and heparin on the pregnancy outcome in women with antiphospholipid syndrome
2022, Annals of Medicine and SurgeryCitation Excerpt :For refractory APS, defined as the persistence of recurrent miscarriage despite standard therapy, treatment options include low-dose glucocorticoids, hydroxychloroquine (HCQ), immunoglobulin, and plasmapheresis [7]. Traditional treatment with prednisone + aspirin was described by Lubbe et al., in 1983 as an effective and economical therapy to prevent pregnancy loss [5,12,13]. However, The use of prednisone in conjunction with low-dose aspirin does not seem to improve pregnancy outcomes according to Silver et al. [14], and prednisone-associated morbidity has led to the use of the combination of heparin + aspirin [15].
Implications of long-term medication of oral steroids and antimalarial drugs in primary Sjögren's syndrome
2011, International ImmunopharmacologyCitation Excerpt :In our cohort, there is no difference in the volume of unstimulated whole saliva in patient groups, and Haldorsen et al. [31] concluded that neither antimalarial nor oral steroid treatment gave significant differences in 30% increase or decrease of unstimulated whole saliva. Previous studies have shown prednisolone to decrease autoantibody levels in patients with anticardiolipin antibodies [32] or have no effect at all on antibody response to vaccines [33], and the SPC [25] state that glucocorticoids do not seem to have a significant effect on circulating antibodies at therapeutic dose levels. A small study, comprising only of 20 patients and no controls, found that low-dose prednisolone significantly reduced levels of Ro/SSA and La/SSB antibodies in primary Sjögren's syndrome [30], and that this effect was sustained after 48 months follow up of 5 patients.
Treatment of Antiphospholipid Syndrome
2011, Systemic Lupus ErythematosusTreatment of Antiphospholipid Syndrome
2010, Systemic Lupus Erythematosus, Fifth EditionTreatment of antiphospholipid syndrome in pregnancy
2006, Seminarios de la Fundacion Espanola de Reumatologia
- ☆
This work was supported in part by a grant from the Arthritis Foundation, Florida Chapter, and The Tampa Chapter of the Lupus Foundation, and it was presented in part at the Southern Meeting of the Society of American Federation for Clinical Research, New Orleans, January 30–February 1, 1991, and at the 55th Annual Meeting of the American College of Rheumatology, Boston, November 17–21, 1991.